PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)

2013-10-29
(Press-News.org) Contact information: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin) A University of Colorado Cancer Center study published in the journal PLOS ONE shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor. This change to new growth-factor dependence may allow colorectal cancer to push past bevacizumab's blockage of VEGF-A to continue to drive tumor growth.

"Think of it like damming a river. Bevacizumab can block the main flow, but then once a tumor's need builds up behind this dam, water starts to flow around the blockage in the form of streams and tributaries. That's like these other growth factors – eventually a tumor becomes able to use these tributaries of VEGF-C, VEGF-D and placental growth factor to supply itself with the 'water' it needs," says Christopher Lieu, MD, investigator at the CU Cancer Center and assistant professor of Medical Oncology at the University of Colorado School of Medicine.

The analogy of liquid is an apt one – bevacizumab slows cancer's growth by limiting a tumor's ability to grow the new blood vessels it needs to supply itself with nutrients. Especially in combination with chemotherapy, bevacizumab has proved an effective treatment for colorectal cancer. But then there frequently comes a point at which bevacizumab stops working and the tumor restarts its growth. This study asked why.

Specifically, Lieu and colleagues serially tested the levels of other VEGF-related growth factors in 42 patients treated with bevacizumab and chemotherapy, at many points during the course of their treatment.

"What we saw is that levels of VEGF-C and placental growth factor went up just before tumors progressed and then stayed high during the periods of tumor growth. Interestingly, VEGF-D was only elevated during progression. But it seems that tumors may be using these growth factors as ways to create blood vessel growth in the absence of VEGF-A, blocked by bevacizumab," Lieu says.

Then the researchers also took a snapshot of levels in 403 colorectal cancer patients, at one time during treatment. Because this group included patients who were and were not being treated with chemotherapy along with bevacizumab, they could show that the rise in VEGF levels was, in fact, due to bevacizumab and not to some interaction with the chemotherapy.

"It's too early to say with certainty that VEGF-C, VEGF-D, and placental growth factor are the cause of colorectal cancer resistance to bevacizumab, but the correlation we saw in this study is compelling," Lieu says.

Current studies are exploring the use of drugs that block more blood-vessel-growth-promoting factors than VEGF-A. For example, Lieu points to the example of aflibercept (Zaltrap), which was given FDA approval in August, 2013 for the treatment of metastatic colorectal cancer, along with the chemotherapy regimen known as FOLFIRI. The drug inhibits placental growth factor along with VEGF-A.

"It's an attractive strategy, and also proof of concept that by targeting not only the primary mechanism of tumor growth but also one or more of these 'workarounds,' this drug or other future drugs could stall growth longer than blocking any one of these growth factors, individually," Lieu says.

Lieu points out that in addition to targeting these additional growth factors, the fact that spikes in VEGF-C and placental growth factor presage tumor progression could give doctors and researchers a clue that bevacizumab has lost its efficacy. Though more work is needed, Lieu can imagine using spikes in VEGF-C or prenatal growth factor to recommend evaluating new treatment options.

INFORMATION:

END



ELSE PRESS RELEASES FROM THIS DATE:

U of M researchers identify key proteins influencing major immune strategies

2013-10-29
U of M researchers identify key proteins influencing major immune strategies Findings could help define new vaccination applications MINNEAPOLIS/ST. PAUL (October 27, 2013) – New research from the Masonic Cancer Center, University of Minnesota, ...

UT Dallas study shows experts' attitudes influence what children believe

2013-10-29
UT Dallas study shows experts' attitudes influence what children believe Children are more apt to believe a nice, non-expert than a mean expert according to researchers at The University of Texas at Dallas. In the study published in Developmental Science, ...

Microbiome in gut, mouth, and skin of low birth weight infants differentiate weeks after birth

2013-10-29
Microbiome in gut, mouth, and skin of low birth weight infants differentiate weeks after birth Low birth weight infants are host to numerous microorganisms immediately after birth, and the microbiomes of their mouths and gut start out very similar but differentiate ...

GW researchers examine increased ER reimbursements after ACA insurance coverage expansions

2013-10-29
GW researchers examine increased ER reimbursements after ACA insurance coverage expansions WASHINGTON (Oct. 28, 2013) – Researchers at the George Washington University School of Medicine and Health Sciences (SMHS) found that outpatient emergency department encounters ...

HIV -- Geneticists map human resistance to AIDS

2013-10-29
HIV -- Geneticists map human resistance to AIDS Do our genes hold the key to future AIDS therapies? Using a supercomputer, scientists analyzed the genomes of thousands of strains of the HIV virus and have produced the first map of human AIDS ...

Obamacare could reverse long trend of uncompensated care in ERs

2013-10-29
Obamacare could reverse long trend of uncompensated care in ERs WASHINGTON — Emergency departments, which have suffered shortfalls in reimbursement for decades due to the high rate of uninsurance in the United States, may begin receiving "considerably ...

People seem more attractive in a group than they do apart

2013-10-29
People seem more attractive in a group than they do apart People tend to be rated as more attractive when they're part of a group than when they're alone, according to findings published in Psychological Science, a journal of the Association ...

Study finds new genetic error in some lung cancers

2013-10-28
Study finds new genetic error in some lung cancers May offer target for therapies in patients BOSTON – A fine-grained scan of DNA in lung cancer cells has revealed a gene fusion – a forced merger of two normally separate genes – that spurs the cells to ...

Timely, effective treatment of rheumatoid arthritis reduces disability 2 years out

2013-10-28
Timely, effective treatment of rheumatoid arthritis reduces disability 2 years out Discouraging patients from delaying treatment could reduce disability from RA, according to study Delaying treatment for rheumatoid arthritis could greatly increase the likelihood ...

Study identifies biomarker linked to poor outcomes in pregnant lupus patients

2013-10-28
Study identifies biomarker linked to poor outcomes in pregnant lupus patients Researchers at Hospital for Special Surgery in New York City have identified a biomarker that may predict poor pregnancy outcomes in lupus patients. The study, titled "Angiogenic Factor ...

LAST 30 PRESS RELEASES:

New post-hoc analysis shows patients whose clinicians had access to GeneSight results for depression treatment are more likely to feel better sooner

First transplant in pigs of modified porcine kidneys with human renal organoids

Reinforcement learning and blockchain: new strategies to secure the Internet of Medical Things

Autograph: A higher-accuracy and faster framework for compute-intensive programs

Expansion microscopy helps chart the planktonic universe

Small bat hunts like lions – only better

As Medicaid work requirements loom, U-M study finds links between coverage, better health and higher employment

Manifestations of structural racism and inequities in cardiovascular health across US neighborhoods

Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity

Continuous glucose monitoring frequency and glycemic control in people with type 2 diabetes

Bimodal tactile tomography with bayesian sequential palpation for intracavitary microstructure profiling and segmentation

IEEE study reviews novel photonics breakthroughs of 2024

New method for intentional control of bionic prostheses

Obesity treatment risks becoming a ‘two-tier system’, researchers warn

Researchers discuss gaps, obstacles and solutions for contraception

Disrupted connectivity of the brainstem ascending reticular activating system nuclei-left parahippocampal gyrus could reveal mechanisms of delirium following basal ganglia intracerebral hemorrhage

Federated metadata-constrained iRadonMAP framework with mutual learning for all-in-one computed tomography imaging

‘Frazzled’ fruit flies help unravel how neural circuits stay wired

Improving care for life-threatening blood clots

Yonsei University develops a new era of high-voltage solid-state batteries

Underweight and unbalanced: Gut microbial diversity in underweight Japanese women

Astringent, sharper mind: Flavanols trigger brain activity for memory and stress response

New editorial urges clinicians to address sex-based disparities in sepsis treatment

Researchers at MIT develop new nanoparticles that stimulate the immune system to attack ovarian tumors

Opening the door to a vaccine for multiple childhood infections

New clue to ALS and FTD: Faulty protein disrupts brain’s ‘brake’ system

Detailed map of US air-conditioning usage shows who can beat the heat — and who can’t

An electronic fiber for stretchable sensing

New image captures spooky bat signal in the sky

Cobalt single atom-phosphate functionalized reduced graphene oxide/perylenetetracarboxylic acid nanosheet heterojunctions for efficiently photocatalytic H2O2 production

[Press-News.org] Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)